Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Se Hoon Lee

Showing results (101-110 of 513) with videos related to

Pageof 52
Sort By:
Investigational New Drugs|January 1, 2022
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancerBo Mi Ku, Jae Yeong Heo, Jinchul Kim, et al.
Oncology|February 23, 2022
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR InhibitorBo Mi Ku, Yeon Jeong Kim, Donghyun Park, et al.
Oncotarget|October 6, 2017
Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i>-mutant non-small cell lung cancerBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
Leukemia & Lymphoma|November 11, 2014
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisoneBhumsuk Keam, Hyerim Ha, Tae Min Kim, et al.
Cancer Research and Treatment|March 7, 2024
Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid CancerYoungkyung Jeon, Sehhoon Park, Se-Hoon Lee, et al.
JAMA|April 10, 2014
Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysisJune-Koo Lee, Seokyung Hahn, Dong-Wan Kim, et al.
Cancer Medicine|February 7, 2020
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidenceSeonggyu Byeon, Jang Ho Cho, Hyun Ae Jung, et al.
Cancer Research and Treatment|April 14, 2015
Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab EraHyerim Ha, Bhumsuk Keam, Tae Min Kim, et al.
Scientific Reports|February 7, 2025
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancerJi Eun Shin, Hyun Ae Jung, Sehhoon Park, et al.
Cancers|August 27, 2021
Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung AdenocarcinomaYeonu Choi, Jaehong Aum, Se-Hoon Lee, et al.
Pageof 52

Showing results (101-110 of 513) with videos related to

Sort By:
Pageof 52
Investigational New Drugs|January 1, 2022
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancerBo Mi Ku, Jae Yeong Heo, Jinchul Kim, et al.
Oncology|February 23, 2022
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR InhibitorBo Mi Ku, Yeon Jeong Kim, Donghyun Park, et al.
Oncotarget|October 6, 2017
Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i>-mutant non-small cell lung cancerBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
Leukemia & Lymphoma|November 11, 2014
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisoneBhumsuk Keam, Hyerim Ha, Tae Min Kim, et al.
Cancer Research and Treatment|March 7, 2024
Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid CancerYoungkyung Jeon, Sehhoon Park, Se-Hoon Lee, et al.
JAMA|April 10, 2014
Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysisJune-Koo Lee, Seokyung Hahn, Dong-Wan Kim, et al.
Cancer Medicine|February 7, 2020
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidenceSeonggyu Byeon, Jang Ho Cho, Hyun Ae Jung, et al.
Cancer Research and Treatment|April 14, 2015
Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab EraHyerim Ha, Bhumsuk Keam, Tae Min Kim, et al.
Scientific Reports|February 7, 2025
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancerJi Eun Shin, Hyun Ae Jung, Sehhoon Park, et al.
Cancers|August 27, 2021
Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung AdenocarcinomaYeonu Choi, Jaehong Aum, Se-Hoon Lee, et al.
Pageof 52